A Novel Basal Long-Acting Insulin Analog Toujeo SoloStar®: Benefits for a Patient
A novel human insulin analog glargine (rDNA origin) for injections 300 U/ml (Toujeo SoloStar®) is discussed in the paper. A volume of glargine injected to patients for the same amount of insulin 300 U/ml units was equal to one third of the volume of insulin 100 U/ml. It results in decreasing precipitate surface area and, subsequently, gradual insulin release. Clinical study Phase Ша EDITION demonstrated that insulin analog glargine applied at dose of300 U/ml was comparable with glargine 100 U/ml in terms of efficacy and safety in patients with type 1 and type 2 diabetes mellitus, with lower risk of developing hypoglycemic conditions and body weight gain.